

学医学部倫理委員会承認番号 20140156 UMIN 登録
番号 UMIN000016401。トラニラストを用いた医師主
導型臨床研究を開始した。

D. 考察

前臨床試験により、投与方法は臨床に近い経口投
与が最も有効であることが示された。前臨床試験に
よりトラニラスト投与が骨髄細胞のレシピエントへ
の生着を阻害しないことを確かめた。移植後 2 週時
と 3 週時の血球系細胞の生着を調べたところ、阻害
せずドナー細胞が生着することが確かめられた。ト
ラニラスト投与により病態に関与する T 細胞の増殖
を抑制している可能性が考えられた。また倫理委員
会の承認のもとトラニラストの臨床試験を開始する
ことができた。順調に症例のリクルートが進められ
ており適応拡大の実現にむけて臨床研究がすすめら
れていると考える。

E. 結論

前臨床試験の結果をうけ臨床試験のための倫理委員
会承認を得て医師主導型臨床試験が開始された。今後
の臨床研究の遂行のために、基礎と臨床教室が一体と
なって薬剤の安全性、有効性の検討をすすめる。

F. 健康危険情報

特記すべきものなし

G. 研究発表

1 論文発表

- 1) Nobusue H, Onishi N, Shimizu T, Sugihara E, Oki Y, Sumikawa Y, Chiyoda T, Akashi K, Saya H, Kano K. Regulation of MKL1 via actin cytoskeleton dynamics drives adipocyte differentiation. Nat Commun 5:3368, 2014
- 2) Ishimoto T, Sugihara H, Watanabe M, Sawayama H, Iwatsuki M, Baba Y, Okabe H, Hidaka K, Yokoyama N, Miyake K, Yoshikawa M, Nagano O, Komohara Y, Takeya M, Saya H, Baba H. Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation. Carcinogenesis 35:1003-1011, 2014
- 3) Shimizu T, Sugihara E, Yamaguchi-Iwai S, Tamaki S, Koyama Y, Kamel W, Ueki A, Ishikawa T, Chiyoda T, Osuka S, Onishi N, Ikeda H, Kamei J, Matsuo K, Fukuchi Y, Nagai T, Toguchida J, Toyama Y, Muto A, Saya H. IGF2

preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress. Cancer Res 74:6531-6541, 2014

- 4) Nishio H, Yaguchi T, Sugiyama J, Sumimoto H, Umezawa K, Iwata T, Susumu N, Fujii T, Kawamura N, Kobayashi A, Park J, Aoki D, Kawakami Y. Immunosuppression through constitutively activated NF- κ B signalling in human ovarian cancer and its reversal by an NF- κ B inhibitor. Br J Cancer. 110(12):2965-74, 2014
- 5) Kitano I, Ito R, Kamisako T, Eto T, Ogura T, Kawai K, Suemizu H, Takahashi T, Kawakami Y, Ito M. NOD-Rag2null IL-2R γ null mice: an alternative to NOG mice for generation of humanized mice. Exp Anim. 63(3):321-30, 2014
- 6) Tatematsu Y, Ogawa Y, Abe T, Kamoi M, Uchino M, Saijo-Ban Y, Yaguchi S, Mukai S, Mori T, Okamoto S, Tsubota K. Comparisons for grading chronic ocular graft-versus-host disease: NIH eye score, Japanese dry eye score, and DEWS 2007 score. 2014 Oct; Sci Rep. 4: 6680.
- 7) 河上 裕. がん免疫療法. 医学のあゆみ .249(5):456-455.2014.5.
- 8) 小川葉子. ドライアイ 今日の治療指針 2014 年版 医学書院 1314-1316. 2014.

2 学会発表

- 1) Kawakami Y, Combination Immunotherapy Based on the Cancer Cell's Characteristics and Patients' Immune Status., The 45th International Symposium of The Princess Takamatsu Cancer Research Fund, Palace Hotel Tokyo/Japan, 2014/11/18,
- 2) Kawakami Y, Sugiyama J, Nishio H, Hayakawa T, Iwata T, Aoki D, Yaguchi T., Development of Immunotherapy based on the immunological characteristics of Gynecologic Cancers, The 19th Japan-Korea Cancer Research Workshop, Jeju, Korea, 2014/11/29,
- 3) Ogawa Y, Shimmura S, Suzuki T, Kawai M, Tsubota K. Macrophage expressing oxidative stress marker play some role in lacrimal gland of chronic graft-versus-host disease. The Annual Meeting of Association for Research in Vision and Ophthalmology 2014 (ARVO2014) USA, May, 4-8,

2014.

- 4) Ogawa Y. [IS-SA-167] New Concepts in Ocular Surface Inflammation. The Role of Donor Mesenchymal Stem Cells in cGVHD. World Ophthalmology Congress of the International Council of Ophthalmology (WOC2014), Tokyo, April, 2-6, 2014
- 5) 小川葉子, 河合正孝, 榛村重人, 大多茂樹, 川村直, 鈴木孝典, 桑名正隆, 河上 裕, 坪田一男. 重症ドライアイへの老化マクロファージの関与. 第 19 回シェーグレン症候群セミナー 東京 2014/5/24
- 6) 小川葉子. Special Lecture 2 重症ドライアイの基礎と臨床をつなぐ
第 3 回 Shinjuku Ophthalmology Club 東京 2014/12/18

H. 知的財産権の出願・登録状況（予定を含む）

1. 特許取得
特記すべきものなし
2. 実用新案登録
特記すべきものなし
3. その他
特記すべきものなし

IV. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧表

研究発表・論文発表

【金井 隆典、佐藤 俊朗】

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Sakuraba A, Okamoto S, Matsuoka K, <u>Sato T</u> , Naganuma M, Hisamatsu T, Iwao Y, Ogata H, <u>Kanai T</u> , Hibi T.	Combination Therapy with Infliximab and Thiopurine Compared to Infliximab Monotherapy in Maintaining Remission of Postoperative Crohn's Disease.	Digestion	91	233-8	2015
Seishima R, Wada T, Tsuchihashi K, Okazaki S, Yoshikawa M, Oshima H, Oshima M, <u>Sato T</u> , Hasegawa H, Kitagawa Y, Goldenring JR, Saya H, Nagano O.	Ink4a/Arf-dependent Loss of Parietal Cells Induced by Oxidative Stress Promotes CD44-dependent Gastric Tumorigenesis.	Cancer Prev Res.		canprevres.0025	2015
Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, Watanabe T, <u>Kanai T</u> , <u>Sato T</u> .	Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids.	Nature Medicine	21(3)	256-62	2015
Oshima H, Nakayama M, Han TS, Naoi K, Ju X, Maeda Y, Robine S, Tsuchiya K, <u>Sato T</u> , Sato H, Taketo MM, Oshima M.	Suppressing TGFβ signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer.	Cancer Res.	75(4)	766-76	2015
Pin C, Parker A, Gunning AP, Ohta Y, Johnson IT, Carding SR, <u>Sato T</u> .	An individual based computational model of intestinal crypt fission and its application to predicting unrestrictive growth of the intestinal epithelium.	Integr Biol (Camb).	7(2)	213-28	2015
Simmini S, Bialecka M, Huch M, Kester L, van de Wetering M, <u>Sato T</u> , Beck F, van Oudenaarden A, Clevers H, Deschamps J.	Transformation of intestinal stem cells into gastric stem cells on loss of transcription factor Cdx2.	Nature Communications	5	5728	2014
Saigusa K, Hisamatsu T, Handa T, Sujino T, Mikami Y, Hayashi A, Mizuno S, Takeshita K, <u>Sato T</u> , Matsuoka K, <u>Kanai T</u> .	Classical Th1 cells obtain colitogenicity by co-existence of RORγt-expressing T cells in experimental colitis.	Inflamm Bowel Dis.	20(10)	1820-7	2014
Mizuno S, Mikami Y, Kamada N, Handa T, Hayashi A, <u>Sato T</u> , Matsuoka K, Matano M, Ohta Y, Sugita A, Koganei K, Sahara R, Takazoe M, Hisamatsu T, <u>Kanai T</u> .	Cross-talk between RORγt+ innate lymphoid cells and intestinal macrophages induces mucosal IL-22 production in Crohn's disease.	Inflamm Bowel Dis.	20(8)	1426-34	2014
Mikami Y, Mizuno S, Nakamoto N, Hayashi A, Sujino T, <u>Sato T</u> , Kamada N, Matsuoka K, Hisamatsu T, Ebinuma H, Hibi T, Yoshimura A, <u>Kanai T</u> .	Macrophages and dendritic cells emerge in the liver during intestinal inflammation and predispose the liver to inflammation	PLoS One.	9(1)	e84619.	2014

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Takabayashi K, Kashiwagi K, Kawata T, <u>Sato T</u> , Matsuoka K, Hisamatsu T, Takaishi H, Hibi T, Ogata H, Yahagi N, Kitagawa Y, Shigematsu N, <u>Kanai T</u> .	Continuous low-dose irradiation by I-125 seeds induces apoptosis of gastric cancer cells regardless of histological origin.	Cancer Biol Ther.	15(1)	81-8	2014
Ohta Y, <u>Sato T</u> .	Intestinal tumor in a dish.	Front Med (Lausanne)	1	14	2014
Fujii M, <u>Sato T</u>	Culturing intestinal stem cells: applications for colorectal cancer research.	Front Genet.	5	169	2014

【金井 隆典、長沼 誠】

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
<u>Naganuma M</u> , Hosoe N, Ogata H.	Endoscopic and pathologic changes of the upper gastrointestinal tract in Crohn's disease.	Dig Endosc	Suppl 1	20-28	2014
Mikami Y, Mizuno S, Nakamoto N, Hayashi A, Sujino T, Sato T, Kamada N, Matsuoka K, Hisamatsu T, Ebinuma H, Hibi T, Yoshimura A, <u>Kanai T</u> .	Macrophages and dendritic cells emerge in the liver during intestinal inflammation and predispose the liver to inflammation.	PLoS One.	2:9	e84619	2014
<u>Naganuma M</u> , Hisamatsu T, <u>Kanai T</u> , Ogata H.	Magnetic resonance enterography of Crohn's disease.	Expert Rev Gastroenterol Hepatol.	Sep 3	1-9	2014
Kurtz CC, Drygiannakis I, <u>Naganuma M</u> , Feldman SH, Bekiaris V, Linden J, Ware CF, Ernst PB.	Extracellular Adenosine Regulates Colitis through Effects on Lymphoid and Non-Lymphoid Cells.	Am J Physiol Gastrointest Liver Physiol.	307	G338-46	2014
Takenaka K, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E, <u>Naganuma M</u> , Araki A, Watanabe M.	Comparison of Magnetic Resonance and Balloon Enteroscopic Examination of Deep Small Intestine in Patients with Crohn's Disease.	Gastroenterology.	47	334-342	2014
Saigusa K, Hisamatsu T, Handa T, Sujino T, Mikami Y, Hayashi A, Mizuno S, Takeshita K, Sato T, Matsuoka K, <u>Kanai T</u> .	Classical Th1 cells obtain colitogenicity by co-existence of ROR γ t-expressing T cells in experimental colitis.	Inflamm Bowel Dis.	20	1820-7.	2014
Matano M, Date S, Shimokawa M, Takano A, Fujii M, Ohta Y, Watanabe T, <u>Kanai T</u> ,	Modelling colorectal cancer using CRISPR-Cas9-mediated	Nature Medicine	21(3)	256-62	2015

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Mizuno S, Mikami Y, Kamada N, Handa T, Hayashi A, Sato T, Matsuoka K, Matano M, Ohta Y, Sugita A, Koganei K, Sahara R, Takazoe M, Hisamatsu T, <u>Kanai T</u> .	Cross-talk between ROR γ t ⁺ innate lymphoid cells and intestinal macrophages induces mucosal IL-22 production in Crohn's disease.	Inflamm Bowel Dis.	20	1426-34	2014
Matsuoka K, <u>Kanai T</u> .	Gut microbiota and inflammatory bowel disease.	Seminars in Immunopathol.	37(1)	47-55	2014

【竹内 勤、金子 祐子】

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Shirai Y, Okazaki Y, Inoue Y, Tamura Y, Yasuoka H, <u>Takeuchi T</u> , and Kuwana M	Elevated pentraxin 3 in systemic sclerosis: Associations with vascular manifestations and defective vasculogenesis.	Arthritis & Rheum	In print		
<u>Takeuchi T</u> , Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Namanaka H, and Miyasaka N	Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective multi-center, observational study in Japan.	Rheumatology (Oxford).	In print		
Kaneko Y, Koike T, Oda H, Yamamoto K, Miyasaka N, Harigai M, Yamanaka H, Ishiguro N, Tanaka Y, and <u>Takeuchi T</u> .	Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan.	Mod Rheum	In print		
Akiyama M, Kaneko Y, Hanaoka H, Kuwana M, and <u>Takeuchi T</u> .	Polychondritis presenting with oculomotor and abducens nerve palsies as initial manifestation.	Mod Rheum	In print		
Iwahashi M, Inoue H, Matsubara T, Tanaka T, Amano K, Kanamono T, Nakano T, Uchimura S, Izumihara T, Yamazaki A, Karyekar C, and <u>Takeuchi T</u>	Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a phase II/III, randomized study.	Mod Rheum	In print		

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Izumi K, Kaneko Y, Yasuoka H, Seta N, Kameda H, Kuwana M, and <u>Takeuchi T</u> .	Tocilizumab is clinically, functionally and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors. A single center retrospective cohort study (KEIO-TCZ study) at 52 week.	Mod Rheum	In print		
Kaneko Y, Kuwana M, Kondo H, and <u>Takeuchi T</u> .	Discordance in global assessments between patient and estimator in patients with newly diagnosed rheumatoid arthritis: associations with progressive joint destruction and functional impairment.	J Rheumatology	40	1061-66	2014
Inaba T, Hisatsune C, Sasaki Y, Sasaki Y, Ogawa Y, Ebisu E, Ogawa N, Matsui M, <u>Takeuchi T</u> , Mikoshiba K, and Tsubota T	Mice lacking inositol 1,4,5-triphosphate receptors exhibit dry eye.	Plos One	9	e99104	2014
<u>Takeuchi T</u> , Matubara T, Urata Y, Suematsu E, Ohta S, Honjyo S, Abe T, Yamamoto A, Miyasaka N, and the Japan Abatacept Study Group	Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate conventional or biologic disease-modifying antirheumatic drugs.	Mod Rheum	244	744-53	2014
Mok CC, Yap DY, Navarra SV, Liu Z-H, Zao M-H, Lu L, <u>Takeuchi T</u> , Avihingsanon Y, Yu X-Q, Lapid EA, Lague-Lizardo LR, Smethkul V, Shen N, Chen S-L, and Chan TM, for the Asian Lupus Nephritis Network	Overview of lupus nephritis management guidelines and perspective from Asia.	Nephrology	19	11-20	2014
Kaneko Y, Hanaoka H, Hirakata M, <u>Takeuchi T</u> , and Kuwana M.	Distinct arthropathies of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients.	Rheumatology	53	1120-24	2014

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Yamanaka H, Ishiguro N, <u>Takeuchi T</u> , Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, and Tanaka Y.	Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.	Rheumatology	53	901-13	2014
Tanaka Y, Yamamoto K, <u>Takeuchi T</u> , Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T	Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.	Mod Rheum	24	734-43	2014
Tanaka Y, Kubo S, Yamanaka H, Amano K, Hirata S, Tanaka E, Nagasawa H, Yasuoka H, and <u>Takeuchi T</u>	Efficacy and safety of abatacept in routine care of patients with rheumatoid arthritis: Orenzia® as Biological Intensive Treatment for RA (ORBIT) study.	Mod Rheumtol	24	754-762	2014
<u>Takeuchi T</u> , Kawai S, Yamamoto K, Harigai M, Ishida K and Miyasaka N.	Post-marketing surveillance of the safety and effectiveness of tacrolimus in 3267 Japanese patients with rheumatoid arthritis.	Mod Rheumtol	24	8-16	2014
Nishina N, Kikuchi J, Hashizume M, Yoshimoto K, Kameda H, and <u>Takeuchi T</u> .	Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy.	Ann Rheum Dis	73	945-7	2014
<u>Takeuchi T</u> , Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Hartmut K, Vipin A, and Tanaka Y.	Adalimumab, a Human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early RA; the HOPEFUL 1 study	Ann Rheum Dis	73	536-43	2014
Kurasawa T, Nagasawa H, Kishimoto M, Amano K, <u>Takeuchi T</u> , and Kameda H.	Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial.	Mod Rheumtol	24	561-6	2014

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Nishimoto T, Seta N, Anan R, Yamamoto T, Kaneko Y, <u>Takeuchi T</u> , and kuwana M.	A single nucleotide polymorphism of TRAF1 predicts the clinical response to anti-TNF treatment Japanese patients with rheumatoid arthritis.	Clin Exp Rheum	32	211-7	2014
Yamamoto K, <u>Takeuchi T</u> , Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, and Koike T.	Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.	Mod Rheumtol	24	552-60	2014
Yamamoto K, <u>Takeuchi T</u> , Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, and Koike T	Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.	Mod Rheumtol	24	715-24	2014
Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, <u>Takeuchi T</u> , Takei S, Tanaka Y, Sano Y, Yamaguchi H, and Yamanaka H.	Characteristics related to good effectiveness and safety with tocilizumab: Post-marketing surveillance of 7901 rheumatoid arthritis patients in Japan.	J Rheumatology	41	15-23	2014
Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, <u>Takeuchi T</u> , Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N.	Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study	Mod Rheumatol	24	26-32	2014
Nishimoto N, Amano K, Hirabayashi Y, Horiuchi T, Ishii T, Iwahashi M, Iwamoto M, Kohsaka H, Kondo M, Matsubara T, Mimura T, Miyahara H, Ohta S, Saeki Y, Saito K, Sano H, Takasugi K, <u>Takeuchi T</u> , Tohma S, Tsuru T, Ueki Y, Yamana J, Hashimoto J, Matsutani T, Murakami M, Takagi N.	Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study	Mod Rheumatol	24	17-25	2014

【河上 裕、佐谷 秀行、小川 葉子】

発表者氏名	論文タイトル	発表誌名	巻号	ページ	出版年
Nobusue H, Onishi N, Shimizu T, Sugihara E, Oki Y, Sumikawa Y, Chiyoda T, Akashi K, <u>Saya H</u> , Kano K	Regulation of MKL1 via actin cytoskeleton dynamics drives adipocyte differentiation.	Nat Commun	5	3368	2014
Ishimoto T, Sugihara H, Watanabe M, Sawayama H, Iwatsuki M, Baba Y, Okabe H, Hidaka K, Yokoyama N, Miyake K, Yoshikawa M, Nagano O, Komohara Y, Takeya M, <u>Saya H</u> , Baba H	Macrophage-derived reactive oxygen species suppress miR-328 targeting CD44 in cancer cells and promote redox adaptation.	Carcinogenesis	35	1003-1011	2014
Shimizu T, Sugihara E, Yamaguchi-Iwai S, Tamaki S, Koyama Y, Kamel W, Ueki A, Ishikawa T, Chiyoda T, Osuka S, Onishi N, Ikeda H, Kamei J, Matsuo K, Fukuchi Y, Nagai T, Toguchida J, Toyama Y, Muto A, <u>Saya H</u>	IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress.	Cancer Res	74	6531-6541	2014
Nishio H, Yaguchi T, Sugiyama J, Sumimoto H, Umezawa K, Iwata T, Susumu N, Fujii T, Kawamura N, Kobayashi A, Park J, Aoki D, <u>Kawakami Y</u> .	Immunosuppression through constitutively activated NF- κ B signalling in human ovarian cancer and its reversal by an NF- κ B inhibitor.	Br J Cancer	110(12)	2965-74	2014
Ktano I, Ito R, Kamisako T, Eto T, Ogura T, Kawai K, Suemizu H, Takahashi T, <u>Kawakami Y</u> , Ito M.	NOD-Rag2null IL-2R γ null mice: an alternative to NOG mice for generation of humanized mice.	Exp Anim.	63(3)	321-330	2014; Published online 2014 Aug 22.
Tatematsu Y, <u>Ogawa Y</u> , Abe T, Kamoi M, Uchino M, Saijyo-Ban Y, Yaguchi S, Mukai S, Mori T, Okamoto S, Tsubota K.	Comparisons for grading chronic ocular graft-versus-host disease: NIH eye score, Japanese dry eye score, and DEWS 2007 score.	Sci Rep	4	6680	2014

・書籍

【竹内 勤、金子 祐子】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
<u>金子祐子</u> 、 <u>竹内 勤</u>	関節リウマチクリニカルクエスチョン		関節リウマチクリニカルクエスチョン		東京	2014	
<u>金子祐子</u>	シェーグレン症候群		ガイドライン外来診療	日経メディカル開発	東京	2014	
<u>金子祐子</u>	抗リウマチ薬	矢崎義雄	治療薬 Up-To-Date	メディカルレビュー社	大阪	2014	610-612
菊池 潤、 <u>竹内 勤</u>	概論-治療標的としてのサイトカインと受容体	田中良哉	サイトカインと受容体	羊土社	東京	2014	80-83

安岡秀剛、 竹内 勤	抗平滑筋抗体、抗横紋筋抗体、血清中デスマグレイン1抗体、血清中デスマグレイン3抗体	中原一彦	検査値事典〔第2版〕	総合医学社	東京	2014	
安部貴人、 竹内 勤	抗アセチルコリン受容体抗体、抗GMI IgG抗体、抗GQ1b IgG抗体	中原一彦	検査値事典〔第2版〕	総合医学社	東京	2014	

【河上 裕、小川 葉子】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
河上 裕	がん免疫療法	小室一成	医学のあゆみ	医歯薬出版株式会社	東京	2014	456-455
小川葉子	ドライアイ	福井次矢、 高木誠 小室 一成	今日の治療指針2014年度版	医学書院	東京	2014	1314-1316

